Trials / Terminated
TerminatedNCT03354637
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-Blind, Vehicle-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily for 6 Months in Adolescents and Adult Subjects With Stable Patchy Alopecia Areata With Optional Long-Term Open-Label Extension
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Primary: • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: • To evaluate key clinical outcome assessments
Detailed description
Primary: • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: • To evaluate key clinical outcome assessments
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI-50002 high dose | Topical solution |
| DRUG | ATI-50002 low dose | Topical solution |
| DRUG | Placebo | Topical solution |
Timeline
- Start date
- 2017-11-29
- Primary completion
- 2019-04-18
- Completion
- 2019-09-10
- First posted
- 2017-11-28
- Last updated
- 2020-06-05
- Results posted
- 2020-06-05
Locations
23 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03354637. Inclusion in this directory is not an endorsement.